Pinuccia Valagussa

机构：Fondazione Michelangelo · ORCID：0000-0003-3590-7916

发表论文 402 篇 · 总被引 36539 次 · h-index 81

代表论文

• Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study (2022 · Annals of Oncology · 被引 405)
• Spatial predictors of immunotherapy response in triple-negative breast cancer (2023 · Nature · 被引 363)
• Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials (2021 · The Lancet Oncology · 被引 361)
• Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials (2023 · The Lancet · 被引 211)
• Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials (2023 · The Lancet · 被引 171)
• Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study (2020 · Cancer Research · 被引 133)